Research
Hormonal
The protective effect of CD38 deficiency against obesity requires intact SIRT1 activity, mediated by increased NAD levels.
NAD levels are crucial for activating SIRT1, which in turn activates PGC1alpha to burn fat. CD38 breaks down NAD, so high CD38 activity might hinder weight loss. Maintaining NAD levels (through exercise or potentially supplements) may support this pathway.
GoodSupportsHIGH confidence
Analysis of the mechanism revealed that this resistance to diet-induced obesity is mediated at least in part via a NAD-dependent activation of SIRT-PGC1alpha axis.
Why this rating
Strong mechanistic evidence using knockout models and biochemical assays.
Source
The enzyme CD38 (a NAD glycohydrolase, EC 3.2.2.5) is necessary for the development of diet‐induced obesity
Maria Thereza Barbosa et al. · The FASEB Journal · 2007
DOI 10.1096/fj.07-8290com
mechanism_onlyCited 252×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →